Novacyt launches two new PCR assays



© Reuters

By Samuel Indyk

Investing.com – Anglo-French diagnostics company Novacyt has launched two new polymerase chain reaction (PCR) assays to expand its genesig COVID-19 and SNPsig SARS-CoV-2 variant detection portfolios.

The AIM-listed company said its new genesig COVID-19 3G test will enable the fulfilment of certain international travel testing requirements, including Fit to Fly Certificate, Test to Release and US FDA regulations.

The second test, its SNPsig EscapePLEX SARS-CoV-2 test, is a single kit which is able to detect the four most critical mutations currently recognised. It is currently a research-use-only kit that detects the biologically significant ‘escape’ mutations E484K, K417N, K417T and P681R, present in the Alpha, Beta, Gamma and Delta Variants of Concern.

“The success of our COVID-19 PCR assays has been built around robust design principles and our real-time bioinformatics surveillance programme to monitor new SARS-CoV-2 genome sequences,” said Novacyt (LON:) Chief Executive Graham Mullis.

“As a result, our genesig® COVID-19 portfolio is highly accurate despite mutations, and we believe our SNPsig® portfolio is the world’s largest for detecting SARS-CoV-2 variants.

“The addition of both of these new assays ensures that Novacyt’s COVID-19 solutions remain robust and that pragmatic options are available to support both public health and private sector testing alike.”

At 10:09BST, shares in Novacyt were trading higher by 1.2% at 349.35 pence per share.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

READ  FedEx to end ground-delivery deal with Amazon - Bloomberg

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here